At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Placebo Administration, and 2 other interventions for Recurrent Lung Small Cell Carcinoma. Active but no longer recruiting, targeting 97 participants across 14 sites.
Signals
Detailed Summary
This randomized phase II trial studies how well temozolomide with or without veliparib works in treating patients with small cell lung cancer that has returned or does not respond to treatment. Temozolomide works by damaging molecules inside the cancer cells, such as deoxyribonucleic acid (DNA), that are needed for cancer survival and growth. Veliparib may stop the growth of tumor cells by blocking proteins that are needed for repairing the damaged DNA and it may also help temozolomide to kill more cancer cells. It is not yet know whether temozolomide is more effective with or without veliparib in treating patients with relapsed or refractory small cell lung cancer.
Study Details
Timeline
Arms & Interventions
Patients receive veliparib PO BID on days 1-7 and temozolomide PO on days 1-5.
Patients receive placebo PO BID on days 1-7 and temozolomide as in Arm I.
Interventions
Correlative studies
Given PO
Given PO
Given PO